| Description | Allopurinol (Zyloric) is a Xanthine Oxidase Inhibitor. The mechanism of action of allopurinol is as a Xanthine Oxidase Inhibitor. |
| In vitro | Allopurinol在大鼠中,可以防止早期酒精性肝损伤的保护作用,极有可能通过阻止NF-κB的氧化剂依赖性激活.Allopurinol在正常大鼠中,显示异常嘧啶代谢连同可能由尿苷得到改善的肾毒性,这表明Allopurinol本质上使嘧啶代谢异常,损伤肾功能.Allopurinol在正常大鼠中,促进了临床改善,伴随寄生虫在血液,皮肤和淋巴结的减少,即使在长期Allopurinol单独给药后,利什曼原虫可能仍存在于感染利什曼原虫的狗的组织中.在施用DNFB致敏小鼠相同剂量别嘌呤醇的正常小鼠中,Allopurinol增加尿的OD排泄到类似于的程度. Allopurinol在总肝脏和线粒体室中,剂量依赖性保护对乙酰氨基酚诱导的细胞损伤,ATP的损耗和氧化型谷胱甘肽含量的增加,而不抑制在小鼠中反应性代谢物的形成. |
| In vivo | 10 mM Allopurinol抑制缺氧-复氧损伤产生的氧黄嘌呤氧化酶的活性。Allopurinol通过增强黄嘌呤氧化酶的活性来减小细胞内Ca2+浓度。Allopurinol在缺血再灌注损伤的新生大鼠心脏中,逆转黄嘌呤氧化酶的活性增加。 |
| Target activity | XO:7.82±0.12 μM |
| Synonyms | Zyloric, 别嘌醇, Zyloprim, Lopurin, 别嘌呤醇 |
| molecular weight | 136.11 |
| Molecular formula | C5H4N4O |
| CAS | 315-30-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 3 mg/mL (22.04 mM) H2O: Insoluble DMSO: 15 mg/mL (110.2 mM), Sonication is recommended. |
| References | 1. Kang SM, et al. Eur J Pharmacol,2006, 535(1-3), 212-219. 2. Horiuchi H, et al. Life Sci,2000, 66(21), 2051-2070. 3. Manna L, et al. Vet J,2008, 177(2), 279-282. 4. Kono H, et al. J Pharmacol Exp Ther,2000, 293(1), 296-303. 5. Jaeschke H, et al. J Pharmacol Exp Ther,1990, 255(3), 935-941. |
| Citations | 1. Chen Y, Xu W, Chen Y, et al. Renal NF-κB activation impairs uric acid homeostasis to promote tumor-associated mortality independent of wasting. Immunity. 2022 2. Liu N, Huang L, Xu H, et al.Phosphatidylserine decarboxylase downregulation in uric acid‑induced hepatic mitochondrial dysfunction and apoptosis.MedComm.2023, 4(4). |